Advertisement

Topics

Latest "Apomorphine Injection Parkinson Disease" News Stories

22:08 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "Apomorphine Injection Parkinson Disease" found in our extensive news archives from over 250 global news sources.

More Information about Apomorphine Injection Parkinson Disease on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Apomorphine Injection Parkinson Disease for you to read. Along with our medical data and news we also list Apomorphine Injection Parkinson Disease Clinical Trials, which are updated daily. BioPortfolio also has a large database of Apomorphine Injection Parkinson Disease Companies for you to search.

Showing "Apomorphine Injection Parkinson Disease" News Articles 1–25 of 14,000+

Saturday 23rd February 2019

Opinion: How do I know about discrimination at top public health universities? I am a Nigerian-American woman and an infectious disease epidemiologist — I lived through it. https://buff.ly/2VaJY7i 

Opinion: How do I know about discrimination at top public health universities? I am a Nigerian-American woman and an infectious disease epidemiologist — I lived through it. https://buff.ly/2VaJY7i 


LEAF Hosts Second Webinar

On Monday, April

[Comment] Technology to overcome clinical inertia in insulin therapy

The evidence that lowering of blood glucose concentrations in diabetes can reduce risk of complications is well established; however, many people with type 2 diabetes do not reach recommended glycaemic targets.1 Type 2 diabetes is typically a progressive disease with stepwise increases in blood glucose-lowering therapy needed to achieve and maintain glucose targets. Data from many health-care syst...


Friday 22nd February 2019

Medical News Today: Sleep apnea: Daytime sleepiness might help predict cardiovascular risk

A recent study finds that people with obstructive sleep apnea who experience the most daytime sleepiness have the highest risk of cardiovascular disease.

A study in @NatureMedicine finds that an immunotherapy drug can be effective in treating people with recurrent glioblastoma. People treated prior to surgery lived nearly twice as long after surgery as the average life expectancy for the disease. https://

A study in @NatureMedicine finds that an immunotherapy drug can be effective in treating people with recurrent glioblastoma. People treated prior to surgery lived nearly twice as long after surgery as the average life expectancy for the disease. https://go.nature.com/2RZWc0w  pic.twitter.com/DiAj9l34S8

[In Context] Valuing qualitative alongside quantitative research

Scientists love statistics; whether the outcome of a randomised controlled trial or the spread of a disease through a population, researchers seek results backed-up by figures. Policymakers love statistics too; it is easy to justify spending X amount of money when it can be shown that it has benefited Y number of people. While quantitative justifications are logically understandable, what about th...

Researchers unravel how specific intestinal microbiota amplify inflammatory reactions in the lungs

The composition of the microbiome - the countless bacteria, fungi and viruses that colonize our body surface, skin, intestines or lungs - makes a decisive contribution to human health or disease.

Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria

[18F]FDG-PET hypometabolism patterns are indicative of different neurodegenerative conditions, even from the earliest disease phase. This makes [18F]FDG-PET a valuable tool in the diagnostic workup of neurodeg...

Older Biologic Age Linked to Elevated Breast Cancer Risk

NewsNIH scientists use epigenetics to help predict disease development.Contributed Author: N

Immunity, microbiota and kidney disease

HIV Infections in US Could be Reduced By Up to 67 Percent by 2030, Study Finds

NewsOnly if ambitious goals for HIV care and treatment are met and targeted prevention interventions for people at risk for HIV are rapidly scaled up. Cont

STAT Plus: Two drugs for a rare, often fatal genetic disease affecting muscles and movement would have to carry much lower price tags to be cost effective, a report concludes. https://buff.ly/2SjvWyv 

STAT Plus: Two drugs for a rare, often fatal genetic disease affecting muscles and movement would have to carry much lower price tags to be cost effective, a report concludes. https://buff.ly/2SjvWyv 

Expanding the Use of Silicon in Batteries, by Preventing Electrodes From Expanding

NewsAn injection of MXene ink fortifies silicon anodes to absorb charge without terminal swelling.Contributed Author: 

STAT Plus: Two drugs for spinal muscular atrophy should be priced how low to be cost effective?

Two drugs for a rare, often fatal genetic disease affecting muscles and movement would have to carry much lower price tags to be cost effective, a report concludes.

Emerging targets of disease-modifying therapy for systemic sclerosis

Bioverativ Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryBioverativ Inc Bioverativ is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technology for the treatment of hemophilia A; and Alprolix, which comprises recombinant coagulation factor IX en...

Alexion’s Rachelle Jacques Jumps to Enzyvant for CEO Role

Enzyvant has named Rachelle Jacques its new CEO. She comes to the Cambridge, MA, rare disease drug developer from Alexion Pharmaceuticals (NASDAQ: ALXN), where she was senior vice president and global franchise head of complement. Her experience also includes senior roles at Shire and Baxalta. Jacques succeeds Alvin Shih, who will continue to advise Enzyvant. […]

STAT Plus: “Patients in America should not suffer or die because of the greed of a drug company.” @SenSanders remains unimpressed with Catalyst over the price of its rare disease drug. https://buff.ly/2E6o5iB 

STAT Plus: “Patients in America should not suffer or die because of the greed of a drug company.” @SenSanders remains unimpressed with Catalyst over the price of its rare disease drug. https://buff.ly/2E6o5iB 

Prognostic value of serum alkaline phosphatase in spinal metastatic disease

Liquid biopsy and minimal residual disease — latest advances and implications for cure

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

MS is more prevalent in the US than previously reported

The prevalence of multiple sclerosis (MS) in the US is nearly double previous estimates. MS is a chronic auto-immune disease...Read More... The post MS is more prevalent in the US than previously reported appeared first on Pharmaceutical Technology.

A disturbing study about children and guns

Children are relatively healthy overall. Although 25% of the American population is under the age of 19, only 2% of annual deaths occur in this age group. There was a time when the contributions of diseases to pediatric death rates were much higher. Declines in deaths from infectious disease or cancer, the result of early diagnosis, […] Find jobs at Careers by KevinMD.com. Search thousand...

Voyager Therapeutics, AbbVie Add Parkinson’s to Gene Therapy Pact

Voyager Therapeutics and AbbVie, already partners developing gene therapies for Alzheimer’s disease, are now expanding their alliance to include Parkinson’s. AbbVie (NYSE: ABBV) is paying Cambridge, MA-based Voyager (NASDAQ: VYGR) $65 million up front under the new deal. Gene therapies use viruses to carry the genetic instructions into cells. The agreement calls for Voyager to […]

Push-up Capacity in Men a Cheap Measure of Heart Function (CME/CE)

(MedPage Today) -- How many push-ups a man can do may predict his heart disease risk, Harvard study shows


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks